medigraphic.com

2013, Number 2

<< Back Next >>

Rev Fac Med UNAM 2013; 56 (2)

Asbestosis and malignant pleural mesothelioma

Echegoyen CR, Rivera RRM

Language: Spanish
References: 25
Page: 5-17
PDF size: 456.53 Kb.


ABSTRACT

Review article considering clinical issues of asbestosis and pleural mesothelioma in the context of a potential pleural mesothelioma outbreak in Mexico in the next 50 years. The common etiologic agent of asbestosis and pleural mesothelioma are asbestos fibers. The history of asbestos dates from 5 000 years ago when Cypriots used it to make their garments, until its industrial usage in the 1870s and its prohibition in some countries after finding its direct relationship with asbestosis, lung cancer, and pleural mesothelioma. The main structural characteristics, chemical profile, and biological properties of asbestos are described here. In Mexico, chrysotile, or white asbestos, is used in 90% of the production of fibercements for the building industry, as well as in components of friction pieces, heating and textile industries. This article analyses the clinical, radiological, histological, and functional issues of asfoto bestosis and pleural mesothelioma; as well as their treatment and prevention. The differential diagnoses for this disease in relation to other respiratory illnesses are described. Since the latent period for both asbestosis and pleural mesothelioma is between 20 and 40 years, an outbreak of pleural mesothelioma can be expected in Mexico in the next 50 years. The only effective way to prevent asbestosis and malignant pleural mesothelioma is banning asbestos-related industries.


REFERENCES

  1. Kishimoto T, Kato K, Arakawa H, et al. Clinical, radiological and pathological investigation of asbestosis. Int J Environ Res Public Health. 2011;8:899-912.

  2. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397-408.

  3. Roggli VL, Gibbs AR, Attanoos R, et al. Pathology of asbestosis. An update of the diagnostic criteria. Arch Pathol Lab Med. 2010;(134):462-80.

  4. Godleski JG. Role of asbestos in etiology of malignant pleural mesothelioma. Thorac Surg Clin. 2004;(14):479-87.

  5. Roach HD, Davies GF, Attanoos R, et al. Asbestos: When the Dust Settles –An Imaging Review of Asbestos-- related Disease. RadioGraphics. 2002;22:S167-S184.

  6. Sebastien P, Janson X, Gaudichet A, et al. Asbestos retention in human respiratory tissues: comparative measurements in lung parenchyma and in parietal pleura. IARC Sci Publ. 1980;30:237-46.

  7. Zellos L, Christiani DC. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin. 2004;(14):469-77.

  8. Wang ZF, Reddy GP, Gotway MB, et al. Malignant Pleural Mesotelioma: Evaluation with CT, MR Imaging, and PET: RadioGraphics. 2004;24:105-19.

  9. Orpella X, Ramírez L, Schlaghecke. Enfermedades relacionadas con los asbestos. MMC. 2007;14(10):610-6.

  10. WHO. Resolution Concerning Asbestos. In: Ninety-fifth International Labour Conference, Geneva, 31 May-16 June 2006. Report of the Committee on Safety and Health. Geneva, International Labour Conference. Annex 20/69.

  11. Kukreja J, Jaklitsch MT, Wiener DC, et al. Malignant pleural mesothelioma: overview of the North American and European experience. Thorac Surg Clin. 2004;(14):435-45.

  12. Aguilar-Madrid L, Juárez PC, Markowitz S, et al. Globalization and the transfer of hazardouz industry: asbestos in Mexico, 1979-2000. Int J Occup Environ Health. 2003;9:272-9.

  13. Bates SE. Clinical applications of serum tumor markers. Ann Intern Med. 1991;115(8):623-38.

  14. Lumb PD, Suvarna SK. Metastasis in pleural mesothelioma. Immunohistochemical markers for disseminated disease. Histopathology. 2004;44:345-52.

  15. Corson JM. Pathology of mesothelioma. Thorac Surg Clin. 2004;(14):447-60.

  16. Méndez VM, López RP, Campos PG, et al. Pleural mesothelioma in paraoccupational environmental and occupational patients exposed to asbestos. Rev Med Inst Mex Seg Soc. 2010;48 (4):361-6.

  17. Tsao AS, Wistuba I, Roth JA, et al. Malignant Pleural Mesothelioma. J Clin Oncol . 2009;27:2081-90.

  18. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;1591-603.

  19. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995;108:1122-8.

  20. Ellis P, Davies AM, Evans WK, et al. The use or chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol. 2006;1:591-601.

  21. Vogelzang NJ. Chemotherapy for malignant pleural mesothelioma. Lancet. 2008;371:1640-2.

  22. Garland L, Flores R, Tsao A. Individualizing mesothelioma treatment: small steps into a brighter future. Clin Lung Cancer. 2010;11(6):371-3.

  23. International Agency for Research on Cancer, Lyon. IARC. Monographs on the evaluation of carcinogenic risk to humans. 1977:14.

  24. Aguilar-Madrid G, Robles-Pérez E, Juárez Pérez C, et al. Estudio de casos y controles de Mesotelioma maligno Pleural en trabajadores con Seguridad Social en México. American Journal of Industrial Medicine. 2009.

  25. WHO. Summary consensus report of WHO workshop on mechanisms of fibre carcinogenesis and assessment of chysotile asbestos substitutes. World Health Organization, Lyon, France. Geneva. 2005, 8-12 November.




2020     |     www.medigraphic.com